MRD Negativity Improved With Isatuximab Plus RVd in Transplant-Eligible Newly Diagnosed Myeloma
December 12th 2021Adding isatuximab to lenalidomide, bortezomib, and dexamethasone demonstrated a superior minimal residual disease rate in patients with transplant-eligible newly diagnosed multiple myeloma.